Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma

Resistance to immunomodulatory drugs (IMiDs(®)) is a major cause of treatment failure, disease relapse and ultimately poorer outcomes in multiple myeloma (MM). In order to optimally deploy IMiDs and their newer derivates CRBN E3 ligase modulators (CELMoDs(®)) into future myeloma therapeutic regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lucia Y., Gooding, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682014/
https://www.ncbi.nlm.nih.gov/pubmed/36439455
http://dx.doi.org/10.3389/fonc.2022.1038329

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682014/
https://www.ncbi.nlm.nih.gov/pubmed/36439455
http://dx.doi.org/10.3389/fonc.2022.1038329

Ejemplares similares